April 1, 2015

The cost of treating rheumatoid arthritis will reach $9.3 billion by 2020, according to a GBI Research report released Wednesday. 

March 31, 2015

Amneal Pharmaceuticals will acquire Actavis Australia's generic pharmaceutical business. Financial terms of the agreement were not disclosed. 

March 31, 2015

The director of the FDA’s Office of Generic Drugs temporarily steps down to deal with a medical issue, according to a report by the Regulatory Focus Professionals Society.

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

March 30, 2015

Teva Pharmaceutical Industries and Auspex Pharmaceuticals announced an agreement under which Teva will acquire Auspex in a deal valued at $3.2 billion.

March 27, 2015

The Food and Drug Adminisration on Friday revisited the issue of supplemental applications proposing labeling changes for approved drugs and biologic products. 

March 24, 2015

Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company.

March 24, 2015

Apotex' Jeff Watson elected to chair the Canadian Generic Pharmaceutical Association on Monday.

March 24, 2015

Dr. Reddy’s Labs has entered into an agreement with Hetero, under which it will be licensed to distribute and market sofosbuvir tablets in 400-mg dosage strength. 

March 24, 2015

A new report by Shoppers Drug Mart and Great-West Life demonstrates the importance of pharmacist interventions in diabetes management.

March 24, 2015

Teva Pharmaceutical Industries on Monday announced that Timothy Wright will be heading business development, strategy and innovation for the company, effective April 13. 

March 17, 2015

A new Harris Poll reveals some surprise findings on Americans' preference for generic or branded drugs.

March 17, 2015

Pharma Dynamics has entered into an agreement with Lupin, in which Lupin will acquire the remaining 40% equity in Pharma Dynamics.

March 17, 2015

Par Pharmaceutical Holdings last week announced that it filed a statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock. 

March 16, 2015

Healthiest You on Monday launched a healthcare price comparison app that helps ascertain the cost of procedures and pharmaceuticals. 

March 13, 2015

An Altarum report found that national health spending increased 5.7% in January 2015 vs. January 2014. 

March 12, 2015

CVS Health’s chief medical officer Troyen Brennan said in an interview with Reuters that the entry of copycat biotech drugs could cut prices of expensive medications by 40% to 50%.

March 11, 2015

A new MIT study published Wednesday suggests that a more powerful H1N1 influenza strain may be making its way through India. 

March 11, 2015

Mylan on Wednesday announced the launch of disulfiram tablets USP in dosage strengths of 250 mg and 500 mg.

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

March 10, 2015

Actavis expanded its portfolio of topicals with the launch of a generic corticosteroid.

March 10, 2015

ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths.

March 10, 2015

The Food and Drug Administration recently published bio-equivalence guidance documents. 

March 10, 2015

Impax Labs completed its acquisition of Tower Holdings (which includes operating subsidiaries CorePharma and Amedra Pharmaceuticals), and Lineage Therapeutics. Impax also announced that it would reshape both the operating and reporting structure of its two divisions.